 Relmada Therapeutics Inc NASDAQ: RLMD priced an upsized underwritten public offering of 8.82 million shares at 17.00 per share, with gross proceeds of approximately 150 million. The offer price represents a discount of almost 8 from the last close price of 18.54 on Wednesday. 